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Abstract: Sigma () receptors, initially described as a subtype of opioid receptors, are now considered unique receptors. 
Pharmacological studies have distinguished two types of  receptors, termed 1 and 2. Of these two subtypes, the 1 re-
ceptor has been cloned in humans and rodents, and its amino acid sequence shows no homology with other mammalian 
proteins. Several psychoactive drugs show high to moderate affinity for 1 receptors, including the antipsychotic haloperi-
dol, the antidepressant drugs fluvoxamine and sertraline, and the psychostimulants cocaine and methamphetamine; in ad-
dition, the anticonvulsant drug phenytoin allosterically modulates 1 receptors. Certain neurosteroids are known to interact 
with 1 receptors, and have been proposed to be their endogenous ligands. These receptors are located in the plasma 
membrane and in subcellular membranes, particularly in the endoplasmic reticulum, where they play a modulatory role in 
intracellular Ca
2+ signaling. Sigma1 receptors also play a modulatory role in the activity of some ion channels and in sev-
eral neurotransmitter systems, mainly in glutamatergic neurotransmission. In accordance with their widespread modula-
tory role, 1 receptor ligands have been proposed to be useful in several therapeutic fields such as amnesic and cognitive 
deficits, depression and anxiety, schizophrenia, analgesia, and against some effects of drugs of abuse (such as cocaine and 
methamphetamine). In this review we provide an overview of the present knowledge of 1 receptors, focussing on 1
ligand neuropharmacology and the role of 1 receptors in behavioral animal studies, which have contributed greatly to the 
potential therapeutic applications of 1 ligands. 
Key Words: Sigma-1 receptors, learning and memory, depression and anxiety, schizophrenia, analgesia, pain, drugs of abuse, 
cocaine.
1. HISTORICAL OVERVIEW: DISCOVERY OF 
SIGMA RECEPTORS AND SIGMA RECEPTOR SUB-
TYPES 
 Sigma  () receptors were first described as a subclass of 
opioid receptors [102] to account for the psychotomimetic 
actions of (±)-SKF-10,047 (N-allylnormetazocine) and other 
racemic benzomorphans. This early confusion was due to the 
complex pharmacology of this racemic compound; later 
studiesshowed that (–)-SKF-10,047 binds to  and  opioids, 
whereas the (+)-isomer lacks affinity for opioid receptors but 
binds to PCP (phencyclidine) binding sites with low affinity, 
and to a different site with high affinity, which currently 
retains the designation of  [reviewed in 112 and 214 
amongst others]. 
 Two  different   sites were distinguished based on their 
different drug selectivity pattern and molecular mass; these 
two  sites are now known as  1 and 2receptors [64]. It was 
reported that 1 binding sites display stereospecificity to-
wards dextrorotatory isomers of benzomorphans, whereas 2
binding sites display reverse selectivity, i.e., levorotatory 
isomers display higher affinity than dextrorotatory isomers 
of  ligands [e.g. 64, 165]. The molecular weight was found 
to differ between the two  receptors subtypes: the 1 recep-
tor is a 29-kDa single polypeptide first cloned in 1996 [55], 
whereas 2 receptors have not yet been cloned and have an 
apparent molecular weight of 18-21.5 kDa according to pho-  
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tolabeling studies [65, 159]. In spite of intensive efforts in 
research on the 2 subtype in recent years [partially reviewed 
in 14; 142, 156, 114], the 1 subtype is much better charac-
terized, and is the focus of this review. 
 Sigma1 receptors have been thoroughly studied in an at-
tempt to elucidate their possible neuropharmacological ap-
plications, mainly in learning and memory processes, depres-
sion and anxiety, schizophrenia, analgesia and some effects 
of certain drugs of abuse. In this review we describe some 
aspects of the general biology of 1 receptors, but focus on 
1 ligand neuropharmacology and the role of 1 receptors in 
behavioral animal studies, which have contributed greatly to 
the understanding of the possible neuropharmacological 
properties of 1 receptors. Non-neuropharmacological effects 
of 1 ligands such as cardiovascular effects or their effects on 
cancer and immunity, and their antitussive effects, are not 
covered in this review. Therefore this review will not go into 
detail on some aspects of 1 receptor knowledge, and not all 
references will be cited. 
2. MOLECULAR CHARACTERISTICS, DISTRIBU-
TION AND PHARMACOLOGICAL PROFILE OF 
SIGMA1 RECEPTORS 
2.1. Cloning and Structure of 1 Receptors 
  Significant progress in our knowledge of  receptors was 
made when the 1 receptor was cloned. The 1 receptor is a 
29-kDa single polypeptide which was first cloned in guinea-
pig liver [55], and later in mouse kidney, a JAR human 
choriocarcinoma cell line, and in the rat and mouse brain 
[reviewed in 54]. The protein is composed by 223 amino 
acids and shows the typical 1 binding profile [55, 84, 180]. Pharmacology and Therapeutic Potential  Current Neuropharmacology, 2008, Vol. 6, No. 4    345
The amino acid sequence of the 1 receptor cloned from the 
human cell line is highly homologous to the 1 receptor 
cloned from the other species [181], and shows no homology 
with other mammalian proteins, but shares approximately 
30% identity with the yeast gene that encodes the C7–C8 
sterol isomerase [141], and contains an endoplasmic reticu-
lum retention signal at the NH2 terminus [55, 179]. Cloning 
of the 1 receptor has contributed greatly to research in this 
field, making it possible to design specific antisense oligode-
oxynucleotides to study 1 receptor function (as will be de-
scribed below) and develop 1-receptor knockout mice [91]. 
  Several structures have been proposed for 1 receptors. 
Initial studies proposed a single transmembrane domain 
structure [43, 55]. More recently, Aydar and coworkers pre-
sented evidence that the 1 receptor in the plasma membrane 
has two transmembrane segments (when expressed in 
Xenopus laevis oocytes) with the NH2 and COOH termini on 
the cytoplasmic side of the membrane [3]. Recent studies 
proposed that in addition to the hydrophobic regions that 
constitute the putative transmembrane domains, there are 
two additional hydrophobic segments (one of them partially 
overlapping the second transmembrane domain), which were 
proposed to be steroid binding domain-like sites [27], and 
suggesting the existence of two different domains for ligand 
binding in the 1 receptor [159], as previously proposed in 
earlier experiments [12]. This proposed model is illustrated 
in Fig. (1). The pharmacological characterization of these 
putative domains merits further study. 
2.2. Anatomical and Subcellular Distribution of 1 Recep-
tors 
2.2.1. Anatomical Distribution of 1 Receptors 
  At the anatomical level 1 receptors are widely distrib-
uted in peripheral organs [e.g. 192] and different areas of the 
central nervous system, where they have been thoroughly 
studied. They are widely distributed in the brain, but concen-
trated in specific areas involved in memory, emotion and 
sensory and motor functions [reviewed in 9, 54 and 146]. In 
these studies high to moderate levels of 1 receptors were 
associated with the hippocampus, especially in the dentate 
gyrus, hypothalamus, olfactory bulb, several cortical layers, 
pons, the septum, the central gray, locus ceruleus, dorsal 
raphe, the substantia nigra pars compacta, the red nucleus 
and various motor cranial nerve nuclei. The cerebellum is 
not particularly enriched in 1 receptors, although some of its 
areas, such as the Purkinje cell layer, have been reported to 
show considerable densities of 1 receptors. In addition to 
the brain, 1 receptors are also numerous in the spinal cord, 
mainly in the superficial layers of the dorsal horn [2]. 
2.2.2. Subcellular Distribution of 1 Receptors 
  The subcellular distribution of 1 receptors was firstly 
studied with radioligand binding in subcellular fractions, and 
more recently with immunochemical methods. Binding ex-




3H](+)-pentazocine showed that 1 re-
ceptors are located in several types of mouse, rat and guinea 
pig brain membrane. These binding sites are more abundant 
in microsomal membranes, which is consistent with the en-
doplasmic reticulum retention signal of the cloned 1 recep-
tor [55, 179], but they are also present in nuclear, mitochon-
drial and synaptic membranes [17, 34, 38, 74]. Immunohis-
tochemical studies further confirmed the existence of 1 re-
ceptors in the endoplasmic reticulum not only in neurons [2], 
but also in many other cell types such as oligodendrocytes 
[160], lymphocytes [43], retinal cells [76] and certain cancer 
cells [62]. Detailed studies by Hayashi and Su in NG108 
cells showed that 1 receptors are located as highly clustered 
globular structures enriched in cholesterol and neutral lipids 
in the nuclear envelope and endoplasmic reticulum [re-
viewed in 62]. In neurons from the rat hypothalamus and 
hippocampus, electron microscopy studies showed that 1
receptor immunostaining was mostly associated with neu-
ronal perikarya, the membrane of mitochondria, some cister-
nae of the endoplasmic reticulum and dendrites, where it was 
localized in the limiting plasma membrane including the 
postsynaptic thickening [2]. 
Fig. (1). Putative model for 1 receptors proposed by Pal and coworkers [159]. Open cylinders represent the two putative transmembrane 
domains. Closed cylinders represent the steroid binding domain-like sites and the open hexagon represents a putative 1 ligand. A, Possible 
spatial arrangement of the ligand binding site involving both steroid binding domain-like sites. B, Alternative model for ligand interaction 
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2.3. Pharmacological Profile of 1 Receptors: Xenobiotics 
and Endogenous Ligands 
2.3.1. Exogenous Ligands for 1 Receptors 
  As described in the introduction, one characteristic that 
distinguishes 1 binding sites from 2 receptors is that the 1
receptor displays stereospecificity towards dextrorotatory 
isomers of benzomorphans (such as SKF-10,047 or pentazo-
cine) [64, 165]. An interesting aspect of 1 receptor pharma-
cology is that these receptors can bind, with high to moderate 
affinity, a wide spectrum of known compounds of very dif-
ferent structural classes and with different therapeutic and 
pharmacologicalapplications, such as neuroleptics (e.g. halo-
peridol, nemopramide), antidepressants (e.g. fluvoxamine, 
clorgyline), antitussives (carbetapentane, dextromethorphan, 
dimemorfan), drugs for the treatment of neurodegenerative 
disorders such as Parkinson’s disease (amantadine) or Alz-
heimer’s disease (memantine, donepezil), and drugs of abuse 
(cocaine, methamphetamine) (Table 1). As for many other 
receptors, some allosteric modulators have been described 
for 1 receptors, including the anticonvulsant drugs pheny-
toin (DPH) and ropizine (Table 1). The modulation of 1
radioligand binding by DPH has been conventionally as-
sumed to be a characteristic difference between 1 and 2
binding sites [see 121 and 165 for reviews]. However, we 
recently reported that DPH also discriminates between dif-
ferent 1 ligands depending on their activities on 1 receptors 
[32, 33]. 
  Haloperidol deserves special consideration among the 
ligands, because it is the most widely used 1 antagonist in 
research on 1 receptors, and its affinity is high enough to 
bind 1 receptors in humans after a single oral dose [192]. In 
fact, haloperidol binds with similarly high affinity to dopa-
mine D2 receptors and  receptors, but its metabolites display 
preferential activity at  receptors compared to dopamine D2
receptors [13]. Particularly interesting is the reduced metabo-
lite of haloperidol (haloperidol metabolite II), which has high 
affinity for 1 and 2 receptors but shows much lower affin-
ity for D2 receptors than the original compound [13, 108]. 
This compound was recently shown to be an irreversible 1
ligand [34]. 
  Some selective and high affinity 1 drugs have been de-
veloped and are considered prototypical 1 ligands. Exam-
ples are the 1 agonists (+)-pentazocine, PRE 084, JO-1784 
and SA4503, and the 1 antagonists BD 1063 and NE-100. 
Table  1 summarizes the pharmacological activities on 1
receptors,  subtype selectivity and other known pharmacol-
ogical activities of some  ligands used in research (and also 
in therapeutics). Currently the number of  ligands is in-
creasing rapidly with the development of new compounds 
[35, 98, 109, 172, among others]. 
2.3.2. Putative Endogenous 1 Ligands: Neurosteroids 
  Although the endogenous ligands for 1 receptors have 
not yet been defined unequivocally, currently the neuroster-
oidsare considered the most probable endogenous 1 ligands. 
This term, first used by Baulieu, identifies steroids that are 
synthesized in the central and peripheral nervous systems, 
andincludespregnenolone,dehydroepiandrosterone (DHEA), 
their sulfate esters, progesterone, and allopregnenolone [re-
viewed in 5]. The physiological actions of neurosteroids in-
clude genomic actions and nongenomic neuromodulatory 
actions, the latter of which are presumably related with 1
receptors [see 146 for a detailed review]. The interaction 
between neurosteroids and 1 receptors was first suggested in 
1988 [193] from in vitro experiments in guinea pig brain and 
spleen. Of the steroids tested, progesterone was the most 
potent inhibitor of 1-specific radioligand binding; however, 
whether neurosteroids are the endogenous ligands of the 1
receptor remains controversial because the affinity of proges-
terone for 1 receptors does not appear to be high enough for 
an endogenous ligand [178]. In addition, other steroids such 
as DHEAS (DHEA sulfate), pregnenolone sulfate, testoster-
one and deoxycorticosterone exhibited even lower affinities 
for 1 receptors than progesterone [61]. However, some re-
ports support that neurosteroids are the 1 receptor endoge-
nous ligands. In many experimental paradigms, progesterone 
behaved like other known 1 antagonists, and DHEA and 
pregnenolone sulfate act as other known 1 agonists [see 127 
and 146 for an extensive review]. The exogenous administra-
tion of neurosteroids led to a dose-dependent inhibition of in
vivo 1 radioligand binding [117, 219], and modifications in 
endogenous levels of neurosteroids (e.g., after adrenalec-
tomy, castration, ovariectomy or during pregnancy) affected 
1 responses [6, 7, 208]. The cloned 1 protein presents ho-
mologies with the steroid binding site of several steroi-
dogenic enzymes, which supports the specific interaction of 
1 receptors with neurosteroids [27, 127, 159]. We have 
therefore included them in Table 1 as putative 1 endogenous 
ligands. 
3. MODULATION OF CELLULAR EFFECTS BY 
SIGMA1 RECEPTORS 
  One of the earliest questions about the cellular effects of 
1 receptors concerned their possible coupling to G-proteins. 
This issue has been studied with different experimental ap-
proaches, and the results reported to date are as profuse as 
they are contradictory [reviewed in 9 and 54]. Even some 
selective 1 agonists seemed to act through G-proteins (JO-
1784), whereas others ((+)-pentazocine) did not under the 
same experimental conditions [143]. Now that the 1 recep-
tor has been cloned [55], it seems clear that the cloned recep-
tor does not have the typical structure of a G-protein-coupled 
receptor with seven transmembrane domains; however, the 
existence of a metabotropic 1 receptor subtype different of 
the cloned type cannot be ruled out yet [e.g. 104]. Although 
the coupling of 1 receptors to G-proteins remains controver-
sial, the modulatory role of 1 receptors in the activity of 
some ion channels, different kinds of neurotransmission 
(mainly glutamatergic) and in second messenger systems, 
particularly the phospholipase C/protein kinase C/inositol 
1,4,5-trisphosphate (PLC/PKC/InsP3) system, has been ex-
tensively reported. 
3.1. Modulation of Plasmalemmal Ion Channels 
3.1.1. Potassium Channels 
  Potassium channels have been shown to constitute an 
important target for  drugs. It has been shown that  ligands 
inhibited K
+ currents in several experimental preparations 
[97, 103, 188, 189, 220, 224]. In some of these studies, Pharmacology and Therapeutic Potential  Current Neuropharmacology, 2008, Vol. 6, No. 4    347








on 1 Site 
Other Activities 
Benzomorphans  
(+)-Pentazocine   1 [61] +++ [61]  Agonist [61]  - 
(–)-Pentazocine   1/2 [214]  ++ [214] Agonist [31]
1 agonist, 1, 2, ligand, low affinity , and 3
opioid ligand [31] 
(+)-SKF-10,047  1 [61]  +++ [61]  Agonist [61]  NMDA receptor ligand [61]
Antipsychotics 
Chlorpromazine  1/2 [108] ++ [61]  ? [61] Dopamine D2 antagonist [61] 
Haloperidol  1/2 [61] +++ [61]  Antagonist [61] 
Dopamine D2 and D3 antagonist [75]; 2 agonist 
[121] 
Nemonapride  1/2? [61]  +++ [61]  ? [61]  Dopamine D2 antagonist [61] 
Antidepressants 
Clorgyline  1 [74]  +++ [74]  Agonist? [9] 
Irreversible monoamine oxidase A inhibitor 
[74] 
Fluoxetine  1 [149]  + [149]  Agonist [61]  Selective 5-HT reuptake inhibitor [149, 61] 
Fluvoxamine  1 [149] +++ [149]  Agonist [61]  Selective 5-HT reuptake inhibitor [149, 61] 
Imipramine  1 [149]  ++ [149]  Agonist [61]  Monoamine reuptake inhibitor [61] 
Sertraline  1 [149] ++ [149]  Agonist [9]  Selective 5-HT reuptake inhibitor [149] 
Antitussives 
Carbetapentane  1/2 [19]  +++ [19] Agonist [121] Muscarinic antagonist [19] 
Dextromethorphan  1 [182] ++ [182]  Agonist [121]  NMDA receptor allosteric antagonist [93]
Dimemorfan  1/2 [182] ++ [182]  Agonist [182, 217]  ? 
Parkinson’s and/or Alzheimer’s disease 
Amantadine  ?  + [162]  Agonist? [162]  NMDA antagonist, antiviral properties [25]
Donepezil  1/2? [82] +++? [82]  Agonist [126, 136,137] Cholinesterase inhibitor [82] 
Memantine  ?  + [162]  Agonist? [162]  NMDA antagonist, antiviral properties [25] 
Drugs of abuse 
Cocaine  1/2 [111] + [61, 111]  Agonist [61] 
Monoamine transporters inhibitor, amongst 
other actions [175] 
MDMA  1/2 [15]  + [15]  ? 
Preferential SERT inhibitor, among other ac-
tions [51] 
Metamphetamine  1/2 [151]  + [151]  ? 
Preferential DAT inhibitor, amongst other 
actions [45] 
Putative endogenous ligands (neurosteroids) 
DHEAS  1 [61]  + [61] Agonist [61]  GABAA negative modulator [121]
Pregnenolone sulfate  1 [61]  + [61]  Agonist [61] 
NMDA positive/GABAA negative modulator 
[121] 
Progesterone  1 [61]  + [32, 33, 70]  Antagonist [61] 
NMDA negative/GABAA positive modulator 
[121] 348    Current Neuropharmacology, 2008, Vol. 6, No. 4 Cobos et al. 


















+channel blocker [152]; T-
type Ca
2+ current inhibitor [202]; Na
+ current 
inhibitor [177] 




Other  drugs 
BD 737  1/2 [65]  +++ [54] Agonist [54] -
BD 1008  1/2 [61] +++ [61]  Antagonist [61] 2 agonist? [120]
BD 1047  1 [107]  +++ [107] Antagonist [107]  adrenoceptor ligand [107]
BD 1063  1 [107]  +++ [107] Antagonist [107]
 - 
BMY 14802  1/2 [108] ++ [108] Antagonist [54] 5-HT1A agonist [106]
DTG  1/2 [61] +++ [61]  ? [61] 2 agonist [121] 
Dup 734  1 [61] +++ [61] Antagonist [54] 5-HT2 antagonist [200]
Eliprodil 
(SL-82.0715) 
1/2 [56]  ++ [56]  ? [61]  NMDA antagonist, 1 adrenoceptor ligand [56] 
E-5842  1 [53] +++ [53]  Antagonist [54]  Low to moderate affinity for dopamine, 5-HT 
and glutamate receptors [53]
Haloperidol 
Metabolite I 




1/2 [108] +++ [34, 108] Irreversible 
antagonist [34] 
Dopamine D2 and D3 ligand [75] 
4-IBP  1/2 [77] +++[77] Agonist [9] Dopamine D2 ligand [77]
JO-1784 (Igmesine)  1 [61] +++ [61]  Agonist [61]  - 
Metaphit  1/2 [11]  ++ [34] Irreversible 
antagonist [11]
Acylator of PCP and 2 binding sites [11] 
(+)-MR 200  1/2 [173]  +++ [173] Antagonist [100]  - 
MS-377  1 [61] +++ [61]  Antagonist [61]  - 
NE-100  1 [61] +++ [61]  Antagonist [61]  - 
OPC-14523  1/2 [61] +++ [61]  Agonist [54]  Agonist of pre- and post-synaptic 5-HT1A re-
ceptors [10]; SERT inhibitor [203] 
Panamesine 
(EMD 57445) 
1/2? [61]  +++? [61] Antagonist [54] One of its metabolites is a dopaminergic an-
tagonist [61] 
(+)-3-PPP  1/2[64]  ++ [32, 33]  Agonist [61] 
2 agonist [121];  
NMDA receptor ligand[68]; dopaminergic 
agonist [61]
PRE 084  1 [61] +++ [61]  Agonist [61]  - 
Rimcazole 
(BW-234U) 
1/2[110] + [61]  Antagonist [61]  DAT inhibitor[110] 
SA4503  1 [61] +++ [61]  Agonist [61]
 - 
SR 31742A  ?  +++ [61]  ?  High affinity for C8-C7 sterol isomerase [61]
* Ki or KD values: +++ < 50 nM; ++ < 500 nM; + < 10 M. 
?: not studied or unclear at the moment. 
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known 1 agonists and antagonists produced the same effects 
[220, 224]. These results might reflect the participation of 2
activity, since it was recently reported that 2 ligands can 
also modulate K
+ currents [142]. However, other recent stud-
ies showed that the selective 1 agonists (+)-pentazocine and 
JO-1784 reduced several K
+ currents in frog melanotropic 
cells [188, 189], and prevented the activation of small-
conductance calcium-activated K
+ channels (SK channels) in 
rat hippocampal slices [103]. These effects were reversed by 
known 1 antagonists (NE-100 or haloperidol) [103, 188]. 
Regarding the molecular mechanism of the effects of 1 re-
ceptors in K
+ currents, it was proposed that 1 receptors and 
K
+ channels must be in close proximity for any functional 
interaction to occur [97, 128], and in fact the heterologous 
expression of 1 receptors with voltage-gated K
+ channels 
Kv 1.4 and 1.5, in Xenopus oocytes, resulted in modulation 
of the channel function in the absence of any  ligand, and 
greater modulation in the presence of SKF-10,047 [3]. 
Moreover, Kv 1.4 channel not only colocalized [128] but 
also co-immunoprecipitated with 1 receptor proteins, indi-
cating that 1 receptors are directly associated with these K
+
channels [3]. In addition, 1 photolabeling with radioiodi-
nated probes identified high-molecular-mass protein com-
plexes, suggesting that 1 receptors may exist as oligomers 
or interact with protein partners either constitutively or 
through ligand binding [159]. The formation of these com-
plexes might help explain the wide variety of actions pro-
duced by 1 ligands in the central nervous system. 
3.1.2. Calcium Channels 
 Sigma1 ligands have also been reported to modulate 
plasmalemmal voltage-dependent calcium channels. Interac-
tion between  receptors and Ca
2+ channels was suggested 
from studies in which the increase in intracellular Ca
2+ con-
centration ([Ca
2+]i) mediated by depolarization was dimin-
ished by  ligands in neuronal cultures or forebrain synapto-
somes [reviewed in 9, 54, 145]. However, in some of these 
experiments  1 agonists and 1 antagonists produced the 
same effects, which might be also due to the participation of 
2 receptors [reviewed in 145]. In addition, the selective 1
agonists (+)-pentazocine and PRE 084 induced opposite ef-
fects on the increase in [Ca
2+]i induced by depolarization 
with KCl in NG108 cells, but both effects were reverted by 
1 receptor antisense oligodeoxynucleotide [59], suggesting 
that they were both mediated by the cloned 1 receptor. It 
therefore seems clear that more studies are necessary to clar-
ify the role of these receptors in plasmalemmal voltage-
dependent calcium channels. 
3.2. Neurotransmitter Systems and 1 Receptors: Modu-
lation of N-methyl-D-aspartate (NMDA) Neurotransmis-
sion 
  Many studies have shown that 1 receptors are able to 
modulate several neurotransmitter systems. It has been re-
ported that 1 receptors can potentiate glutamatergic neuro-
transmission [partially reviewed in 9 and 146], enhance cho-
linergic neurotransmission [partially reviewed in 118; 71], 
enhance serotonergic neurotransmission [reviewed in 9], 
negatively modulate the GABAergic system [47, 148], di-
minish noradrenaline release [20], and modulate dopaminer-
gic neurotransmission [reviewed in 124]. The direction of 
modulation of the dopaminergic system has been especially 
controversial because the contradictory results reported thus 
far make it difficult to reach solid conclusions. The conflict-
ing results probably reflect the use of drugs with different 
degrees of selectivity for 1 receptors, and different routes of 
administration [reviewed extensively in 124]. 
  Among the modulatory effects on different neurotrans-
mitter systems by 1 receptors, the modulation of glutama-
tergic neurotransmission has been described in greater detail 
than others. It has been reported that 1 receptors can en-
hance spontaneous glutamate release in the hippocampus 
[42, 138], potentiate glutamate release induced by brain-
derived neurotrophic factor [222], potentiate the increase in 
[Ca
2+]i induced by glutamate in pyramidal neurons [144], 
and facilitate long-term potentiation in the rat hippocampus 
[26, 94, 103]. Of the three subtypes of glutamate-gated ion 
channels (NMDA, kainate and AMPA-kainate receptors), the 
connection between 1 and NMDA receptors has been 
widely explored, mainly in studies of the NMDA-induced 
firing activity in the dorsal hippocampus. In this model 1
agonistssuchastheselective agonists JO-1784 and (+)-penta-
zocine, the putative agonist DHEA, and the antidepressants 
clorgyline and sertraline (but not paroxetine or tranyl-
cypromine, which showed much lower affinities for 1 re-
ceptors) were able to modulate NMDA-induced firing. The 
effect of these ligands was reversed by known 1 antagonists 
such as haloperidol, NE-100 or BMY-14802, and also by the 
putative endogenous ligand progesterone [reviewed in 9 and 
146]. Interestingly, in these studies 1 agonists showed a 
bell-shaped dose-response curve characterized by low-dose 
stimulation and high-dose inhibition. This type of dose-
response curve indicates hormesis [18], and is well docu-
mented for 1 receptor activation not only in the modulation 
of NMDA-induced firing, but also in many other experimen-
tal approaches, as will be described below. 
  Particularly interesting are the studies that related steroi-
dal tonus under physiological conditions with the -mediated 
potentiation of glutamatergic neurotransmission in the hip-
pocampus. This effect was strongly affected by increased 
levels of progesterone in pregnancy [7], and by decreased 
levels of this neurosteroid after ovariectomy [6]. A molecular 
mechanism was recently proposed by which 1 receptor acti-
vation increases the NMDA receptor response. Ca
2+ entering 
the cells through the NMDA receptors activates a Ca
2+-
activated K
+ current, underlain by SK channels, which in 
turn shunts the NMDA receptor responses. Selective 1 ago-
nists prevented SK channel opening, and consequently in-
creased the NMDA receptor response, emphasizing the im-
portance of the 1 receptor as a postsynaptic regulator of 
synaptic transmission [103]. Importantly, the modulation of 
several neurotransmitter systems mentioned above may be a 
consequence, at least partially, of the modulation of NMDA 
receptors. It has been reported in this connection that 1
ligands can modulate dopaminergic [reviewed in 124], cho-
linergic [reviewed in 146], serotonergic [197] or noradrener-
gic systems [reviewed in 9] through NMDA receptors. 
 In  summary,  1 receptors modulate several neurotrans-
mitter systems, and it seems that the modulation of NMDA 
responses by 1 receptors plays a pivotal role in the modula-
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3.3. Sigma1 Receptors as Modulators of Intracellular 
Messenger Systems 
  The modulation of metabotropic responses by 1 recep-
tors, particularly the increase in [Ca
2+]i after stimulation of 
InsP3 receptors at the endoplasmic reticulum, has been de-
scribed in detail. The mechanism of modulation of the 
PLC/PKC/InsP3 system by 1 receptors appears to be a com-
plex one involving the translocation of 1 receptors to the 
plasma membrane and the nucleus; this was proposed as a 
mechanism by which an intracellular receptor modulates 
metabotropic responses [147, 59]. Sigma1 receptors are lo-
calized in highly clustered globular structures associated 
with the endoplasmic reticulum, which contain moderate 
amounts of free cholesterol and neutral lipids, forming lipid 
droplets [62], in which 1 receptor, ankyrin (specifically the 
ANK220 isomer) and the InsP3 receptors form a complex 
[60]. Sigma1 receptor activation by agonists induces the dis-
sociation of the 1 receptor-ANK220 complex from the InsP3
receptors [60], potentiating the calcium efflux induced by 
receptors that activates the PLC system (such as receptors for 
bradykinin and brain-derived neurotrophic factor) [59, 60, 
70, 162, 222]. The enhancement of calcium efflux, which 
followed a bell-shaped curve [59], has been reported not 
only with known selective 1 agonists such as PRE 084 or 
(+)-pentazocine [59, 60, 70], but also with other compounds 
such as the neurosteroids pregnenolone, pregnenolone sulfate 
and DHEA [59, 70], amantadine and memantine [162]. In 
the presence of a 1 antagonist, 1 receptors are dissociated 
from ankyrin and InsP3 receptors, which remain on the en-
doplasmic reticulum [60] where they impede the potentiation 
by 1 agonists of bradykinin-induced Ca
2+ efflux [59, 70, 
162]. This latter effect was also prevented by the putative 1
antagonist progesterone [59, 70], and by specific 1 receptor 
antisense oligodeoxynucleotides [59]. Under basal condi-
tions 1 ligands did not affect [Ca
2+]i [59, 69], and the cells 
needed to be stimulated to make appropriate levels of InsP3
available for the modulation of [Ca
2+]i by 1 receptor ago-
nists. Additionally, the silencing of InsP3 receptors resulted 
in a decrease in 1 receptor mARN levels [154], underscor-
ing the relationship between this second messenger system 
and 1 receptors. This proposed model of modulation by 1
receptors of InsP3-mediated calcium efflux is illustrated in 
Fig. (2). 
  An additional mechanism by which 1 receptors can 
modulate other receptors located in the plasma membrane 
was recently proposed. It was reported that 1 receptors can 
affect the levels of plasma membrane lipid rafts by changing 
the lipid components therein [199]. This membrane reconsti-
tution could in turn affect the function of the proteins it con-
tains, such as neurotransmitter receptors or tropic factor re-
ceptors. In fact, 1 receptors play an important role in neurite 
sprouting [see 62 for a more complete review]. 
 In  summary,  1 receptors translocate from lipid droplets 
on the endoplasmic reticulum when stimulated by agonists, 
modulating intracellular Ca
2+ mobilizations at the endoplas-
Fig. (2). Model of modulation by 1 receptors of InsP3-mediated calcium efflux, proposed by Hayashi and Su [60, 63]. InsP3 receptors, 
ANK220 and 1 receptor form a complex in lipid droplets on the endoplasmic reticulum, which contain moderate amounts of free cholesterol 
and neutral lipids. In the presence of a 1 agonist, the 1 receptor-ANK220 complex is dissociated from InsP3 receptors and translocated. As 
a result InsP3 binding to its receptor increases and Ca
2+ efflux is enhanced. In the presence of a 1 antagonist, ANK220 remains coupled to 
InsP3 receptor, but 1 receptor is dissociated from the complex, impeding the potentiation of calcium efflux by 1 agonists. Pharmacology and Therapeutic Potential  Current Neuropharmacology, 2008, Vol. 6, No. 4    351
mic reticulum after activation of the PLC/PKC/InsP3 system, 
and enhancing the cellular effects of different receptors. 
4. THERAPEUTIC POTENTIAL OF SIGMA1 RECEP-
TORS 
  Given the widespread distribution of 1 receptors in the 
central nervous system and their modulatory role at cellular, 
biochemical and neurotransmission levels (see above), 1
ligands appear to be useful in different therapeutic fields 
such as depression and anxiety, amnesic and cognitive defi-
cits, psychosis, analgesia and treatment for drugs of abuse. 
These potential therapeutic applications are reviewed briefly 
below. 
4.1. Role of 1 Receptors in Learning and Memory 
  The central cholinergic and glutamatergic neurotransmis-
sion systems play a crucial role in learning and memory 
functions. Cholinergic function is disturbed in some memory 
pathologies such as Alzheimer’s disease and pathological 
ageing, in which deficits in cortical cholinergic activity have 
been observed [4]. In addition, NMDA receptors are in-
volved in the induction of different forms of synaptic plastic-
ity (such as long-term potentiation) which are thought to be 
the synaptic substrate for learning and memory processes 
[166]. As described in the section ‘Neurotransmitter systems 
and  1 receptors: modulation of N-methyl-D-aspartate 
(NMDA) neurotransmission’, 1 agonists facilitate long-term 
potentiation in the rat hippocampus. However, the admini-
stration of large doses of 1 agonists or antagonists (+)-
SKF-10,047, (+)-pentazocine, PRE 084, JO-1784, SA4503, 
DTG, BMY  14802, haloperidol, BD  1047 or NE-100, or 
even the downregulation of 1 receptor expression by an-
tisense oligodeoxynucleotides, failed to affect learning in 
control animals. This finding suggests that 1 receptors are 
not involved in normal memory functions [see 118, 120, 121, 
127, and 146 for reviews]. Bearing in mind the typical 
modulatory role of 1 receptors, it is not surprising that they 
have been found to modulate memory and learning processes 
when a state of pharmacological or pathological imbalance is 
induced. 
4.1.1. Role of 1 Receptors in Memory and Learning Im-
pairment Induced by Drugs, Chemicals or Brain Lesions 
Affecting Cholinergic or Glutamatergic Neurotransmission 
  The learning impairment induced by the cholinergic 
muscarinic antagonist scopolamine, the nicotinic antagonist 
mecamylamine, or by cortical cholinergic dysfunction in-
duced by ibotenic acid injection in the basal forebrain were 
attenuated or reversed by several 1 agonists, including the 
selective 1 agonists (+)-pentazocine, JO-1874 and SA4503 
[reviewed in 118, 121 and 146]. In addition, the memory 
impairments induced by the serotonin (5-HT) depleter p-
chloroamphetamine (PCA), which also involves cholinergic 
dysfunction [115], were attenuated in a bell-shaped manner 
by the administration of (±)-pentazocine, (+)-3-PPP, DTG, 
and (+)-SKF-10,047 [115, 116]. The effects of 1 agonists in 
scopolamine-induced amnesia were reversed by known 1
antagonists including haloperidol and NE-100, and by the 
downregulation of 1 receptor expression by specific an-
tisense oligodeoxynucleotides (reviewed in 118, 121 and 
146). Interestingly, the putative 1 agonists pregnenolone 
sulfate and DHEAS were also effective in scopolamine-
induced amnesia model, and their effects were reversed by 
NE-100 and progesterone [120, 121 and 146]. 
  As noted above, NMDA receptors also play an important 
role in learning and memory processes. The  ligands 
(+)-SKF-10,047, (+)-pentazocine, JO-1784, DTG, PRE 084 
and SA4503, and also the putative endogenous 1 agonists 
DHEAS and pregnenolone sulfate attenuated the learning 
deficits induced by dizocilpine (MK-801), a noncompetitive 
NMDA receptor antagonist, in rats and mice presented with 
different mnesic tasks. The anti-amnesic effect of 1 agonists 
was reverted by several known 1 antagonists such as halop-
eridol, BMY 14802, NE-100 and BD 1047, by the putative 
endogenous 1 antagonists progesterone [partially reviewed 
in 120, 121 and 146; 127], and by the administration of an-
tisense oligodeoxynucleotides against 1 receptors [122, 123, 
126]. Cholinesterase inhibitors such as rivastigmine, tacrine 
and donepezil also attenuated dizocilpine-induced learning 
impairments [126]; however, only the effect of donepezil 
(which is also a potent 1 ligand, see Table 1) was blocked 
by BD 1047 or antisense treatment [126]. 
  Repeated exposure to carbon monoxide (CO) gas induced 
long-lasting but delayed amnesia which was measurable 
about one week after exposure. Like models of ischemia, this 
model involves the neurotoxicity of excitatory amino acids, 
and the hippocampal cholinergic system appears markedly 
affected by hypoxic toxicity [reviewed in 118]. Sigma1
ligands have been shown to have neuroprotective properties 
in models of ischemia [partially reviewed in 118, 16, 81]. 
Consistent with this neuroprotective action is the observation 
that the  ligands (+)-SKF-10,047, PRE 084, JO-1784 and 
DTG reversed CO-induced amnesia, and their effects were 
prevented by NE-100, BMY 14802 and BD 1047 [partially 
reviewed in 120, 135]. Donepezil and some other cholines-
terase inhibitors have also been tested in this behavioral 
model of amnesia, and it was found that all drugs showed 
anti-amnesic properties, but the pre-administration of BD 
1047 blocked only the effect of donepezil [135]. Interest-
ingly, in this model of amnesia the 1 antagonists BD 1008 
and haloperidol also showed anti-amnesic effects that were 
not reversed by NE-100, so it was suggested that these drugs 
might produce their effects through their 2 agonistic activity 
[120]. The role of 1 receptors in these experimental models 
is summarized in Table 2.
4.1.2. Role of 1 Receptors in Cognitive Impairments in 
Ageing: Alzheimer Disease 
  In models related with the memory deficits of ageing, 1
agonists were also effective in attenuating the learning defi-
cits in aged mice, aged rats and in senescence-accelerated 
mice, [reviewed in 118, 146]. Moreover, in the model of 
Alzheimer’s disease-type amnesia induced by 25-35-amyloid 
related peptide, which involves both cholinergic and gluta-
matergic neurotransmission through NMDA receptors [121], 
the 1 receptor agonists (+)-pentazocine, PRE 084, SA4503, 
(+)-SKF-10,047, the antitussive drug dimemorfan and the 
putative  1 agonists DHEAS and pregnenolone sulfate at-
tenuated amnesia in a bell-shaped manner. The effects of 1
agonists were reverted by haloperidol, BD 1047 and the pu-
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and other cholinesterase inhibitors were also tested in this 
behavioral model, but only the effects of donepezil were 
partially reversed by BD  1047, suggesting that the anti-
amnesic effects of this drug involve both its cholinergic and 
1 agonistic properties [137]. These findings are consistent 
with the neuroprotective action of the 1 agonist PRE 084, 
which attenuated cell death in cultured cortical neurons co-
incubated with 25-35-amyloid related peptide, and this effect 
was reversed by the selective 1 antagonist NE-100 [99]. The 
effects of 1 ligands in ageing-related cognitive impairment 
are summarized in Table 2.
4.1.3. Other Ameliorative Effects of 1 Agonists on Learn-
ing and Memory 
  Stress during pregnancy directly affects the neurophysi-
ological development of the fetus with deleterious conse-
quences observable throughout the individual’s lifetime [89], 
and can result in impairments in learning and memory proc-
esses [134]. The 1 agonist JO-1784 reversed the learning 
deficits induced by prenatal stress, in a BD 1063-sensitive 
manner [134]. In addition, it is known that repeated cocaine 
treatment in utero can induce learning and memory impair-
ment in the offspring. It was recently found that this process 
can be reverted by the 1 agonist JO-1784 or DHEA, in a 
BD 1063-sensitive manner [133]. On the other hand, cocaine 
administered at very low doses (much lower doses than those 
which induce learning and memory impairments) can en-
hance memory storage in mice [72]. The ameliorating effects 
of cocaine on memory can be enhanced by the 1 agonist JO-
1784 and also by the putative 1 agonist DHEA, and masked 
by the 1 antagonist BD 1047 and also by the putative 1
antagonist progesterone [171]. The hyperlocomotion, toxic 
effects, and reward properties induced by this psychostimu-
lant are observed at much higher doses, and the effects of 1
Table 2.  Summary of the Effects of 1 Receptors in Experimental Models of Learning and Memory (see References and Text for 
Detailed Information) 
Involvement of 1 Receptors in Learning and Memory 
Behavioral Assays 
Effect of 1 Agonists  Effect of 1 Antagonism 
Scopolamine [121, 146]  Improvement 
Reversion of the effects of 
1 agonists 
Mecamylamine [121] 
Basal forebrain lesion [121, 146] 
PCA [115, 116] 
Improvement Not  tested 
Dizocilpine [120, 121, 122, 123, 
126, 127, 146] 
Drugs, chemicals or brain 
lessions 
CO [16, 81, 118, 120, 135] 
Improvement 
Reversion of the effects of 
1 agonists 
Aged animals [146]  Improvement  Not tested 




heimer disease-type amnesia) [119, 
137, 217] 
Improvement 






nancy Cocaine administration [133] 
Improvement 




Low doses of cocaine [171]  Enhancement  Inhibition 
Effects on mechanisms involved in memory and learning impairment or potentiation 
Impairment 
Neuronal injury induced by ischemia [16, 81, 118] or 25-35-
amyloid-related peptide [99] 
Neuroprotective effects 
Reversion of the effects of 
1 agonists
a
Potentiation  Long-term potentiation [26, 94, 103]  Enhancement 
Reversion of the effects of 
1 agonists 
a Some nonselective 1 antagonists exert neuroprotective effects [reviewed in 118], which may be due to a non-1-mediated mechanism. Pharmacology and Therapeutic Potential  Current Neuropharmacology, 2008, Vol. 6, No. 4    353
ligands on these effects will be described later in section 
4.5.1 on cocaine and 1 receptors. These effects of 1 ago-
nists on cognitive impairment due to alterations during preg-
nancy, as well as their role in the ameliorative effects of low 
doses of cocaine, are summarized in Table 2.
 In  summary,  1 agonists appear to be promising pharma-
cological tools against memory and learning disorders result-
ing from pharmacological or pathological alterations (see 
Table 2). Among the memory and learning disorders, Alz-
heimer’s disease (the most common form of late-life demen-
tia) is characterized by a cognitive decline, and effective 
treatment remains elusive. Sigma1 agonists could thus pro-
vide an alternative treatment against the cognitive deficits of 
this disease. 
4.2. Role of 1 Receptors in Depression and Anxiety 
  Several neurotransmitter systems are important in the 
pathophysiology of depression and anxiety. Depression 
likely involves dysfunction in brain areas that are modulated 
by monoaminergic systems such as the frontal cortex and the 
hippocampus [reviewed in 39]. Given that 1 ligands play a 
modulatory role in several neurotransmitter systems, and that 
they can bind several known antidepressants (Table 1), they 
have been studied as possible pharmacological tools against 
these mood disorders. 
4.2.1. Depression and 1 Receptors 
  The effects of 1 ligands were tested in behavioral studies 
used to predict the antidepressant activity of drugs. The se-
lective  1 agonists SA4503 and (+)-pentazocine decreased 
immobility time in the tail suspension test, and this effect 
was antagonized by NE-100 [207]. Many 1 agonists have 
been tested in the forced swimming test, for example 
SA4503, (+)-pentazocine, JO-1784, DHEAS, pregnenolone 
sulfate, donepezil, and some novel  selective compounds 
such as UMB23, among others. The decrease in immobility 
in the forced swimming test induced by the 1 agonists was 
blocked by known 1 antagonists [partially reviewed in 121; 
126, 185, 208, 210, 218]. Interestingly, the extracts of the 
flowering plant Hypericum perforatum (St. John’s wort), 
which are used as antidepressants, appear to exert their 
therapeutic actions through 1 receptors [reviewed in 132]. 
Additional experiments have related endogenous neuroster-
oidal levels with 1 receptor function. In adrenalectomized 
and castrated mice, the effect of JO-1784 and PRE 084 in the 
forced swimming test was enhanced compared to control 
animals, and these effects were blocked by the selective 1
antagonist BD  1047 [208]. In addition, the antidepressant 
efficacy of the selective agonist JO-1784 was enhanced in 
12-month-old senescence-accelerated (SAM) mice, which 
showed decreased levels of progesterone [163]. Moreover, in 
animals acutely treated with 25-35-amyloid related peptide, 
which does not modify their immobility time, the effects of 
the selective 1 agonists JO-1784 and PRE 084 were facili-
tated, presumably because of a decrease in progesterone lev-
els in the hippocampus [209]. 
  An important consideration is that 1 agonists were able 
to potentiate the firing of serotonergic neurons of the dorsal 
raphe nucleus, as early as after 2 days of treatment, whereas 
SSRI- and monoamine oxidase inhibitor-induced changes 
took several weeks to emerge. The rapid effect of 1 agonists 
has been proposed to predict a more rapid onset of antide-
pressant efficacy compared to existing medications [8]. Be-
cause of the typically modulatory role of 1 receptors, 
OPC-14523, a compound with high affinity for 1 receptors, 
5-HT1A receptors, and serotonin transporter (SERT) (Table 
1) was developed, and was found to produce a marked anti-
depressant-like effect in the forced swimming test after a 
single oral administration. This effect was reversed by both 
1 and 5-HT1A antagonists [203]. Moreover, and also in 
keeping with the modulatory role of 1 receptors, the com-
bined administration of the selective 1 receptor agonist 
(+)-pentazocine and venlafaxine [41], or the co-adminis-
tration of pramipexole and sertraline [167], at subeffective 
doses, showed a synergistic antidepressant-like effect, as did 
the co-administration of SA4503 and memantine or aman-
tadine [186]. Importantly, the antidepressant-like effects of 
these drugs were reversed by known selective 1 antagonists, 
and also by progesterone [41, 167, 186]. 
  It is known that NMDA receptor subunit 1 is decreased 
in the prefrontal cortex or hippocampus of depressive pa-
tients [92, 155]. In the olfactory bulbectomized rat model of 
depression, animals show a decrease in NMDA receptor 
subunit 1 in these areas, and exhibit behavioral deficits 
which resemble the psychomotor agitation, loss of interest, 
and cognitive dysfunction of depression. Repeated treatment 
with SA4503 ameliorated the behavioral deficits, and also 
reversed the decrease in the protein expression of NMDA 
receptor subunit 1. These effects of SA4503 were blocked by 
the co-administration of NE-100 and by acute treatment with 
the NMDA receptor antagonist dizocilpine [216]. These 
findings document the strong relationship between depres-
sion, NMDA receptors and 1 receptors. 
  In addition to the modulatory role of 1 receptors in 
NMDA- and 5-HT-mediated responses related with depres-
sion, a complementary mechanism of action of 1 ligands in 
this disorder has been reported to involve their effects in 
neuroplasticity processes. The mechanism of action of some 
antidepressants may involve neurotrophic actions [150], and 
it was reported that treatment with (+)-pentazocine or the 
antidepressants imipramine and fluvoxamine (which exhibit 
affinity for 1 receptors, see Table 1) enhanced growth fac-
tor-induced neurite sprouting in PC12 cells, and also upregu-
lated 1 receptors [198]. The enhancement of growth factor-
induced neurite sprouting by these drugs was mimicked by 
the overexpression of 1 receptors [199]. 
 In  humans  1 receptors can bind fluvoxamine at thera-
peutic doses [73], suggesting that this receptor might mediate 
some of the effects of this antidepressant; it has also been 
reported that JO-1784, at doses of 20 mg/day, exhibited a 
stronger antidepressant effect than the known antidepressant 
fluoxetine at the same dose in clinical trials. However, at 100 
mg/day JO-1784 was no different from the placebo [9], 
which is in keeping with the bell-shaped dose-response 
curves induced by 1 agonists in several behavioral, bio-
chemical, and electrophysiological paradigms. 
 In  summary,  1 agonists showed good antidepressant 
effects in several behavioral models, probably because of 
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ronal functions as well as their neurotrophic actions (see 
Table 3). Due to the typically modulatory role of 1 recep-
tors, the design of drugs with mixed affinity for 1 and other 
receptors related with depression, and the combined treat-
ment of 1 agonists with known antidepressant drugs, may 
offer good prospects in terms of efficacy. 
4.2.2. Anxiety and 1 Receptors 
  Evidence of anxiolytic activity of 1 ligands was reported 
in the conditioned fear stress model, in which (+)-SKF-
10,047, JO-1784, the neurosteroids pregnenolone sulfate and 
DHEAS, and also the antitussive dextromethorphan attenu-
ated the motor suppression induced by previous electric foot-
shock [79, 80, 153, 211], in a bell-shaped manner [211]. In 
addition, the effects of 1 agonists on motor suppression 
were reversed by the known 1 antagonist NE-100 and pro-
gesterone [153, 211]. In contrast, (+)-pentazocine lacked any 
effect in this model [79, 80]. Interestingly, the concentration 
of 1 active steroids was altered in the plasma and brain of 
stressed mice, and it was therefore hypothesized that en-
dogenous levels of neurosteroids might be involved in the 
expression of conditioned fear stress responses via 1 recep-
tors [153, 211]. In agreement with these results, animals 
treated chronically with 1-40-amyloid related peptide, in 
which progesterone levels in the hippocampus and cortex 
were decreased, exhibited facilitation of the effect of the 1
agonists JO-1784, (+)-SKF-10,047 and DHEAS [211]. 
  The effects of 1 ligands have also been assayed in other 
behavioral tests such as sexual dysfunction induced by stress, 
marble-burying behavior and colonic motor disturbances 
induced by fear. It was reported recently that DHEA attenu-
ated stress-induced sexual dysfunction in rats in a NE-100 
dependent manner [140]. In the marble-burying behavior 
test, considered a potential model of obsessive–compulsive 
disorder on the basis of behavioral similarity, the effect of 
fluvoxamine was antagonized by BD 1063 and BD 1047, but 
not by the 2 antagonist SM-21, suggesting again that the 
interaction of fluvoxamine with 1 receptors contributes to 
its antidepressant effects. In addition, the 1 agonists (+)-
SKF-10,047 and PRE 084 slightly inhibited marble-burying 
behavior [44]. Gue and coworkers [52] showed that JO-1784 
suppressed stress-induced colonic motor disturbances in-
duced by fear stress in rats, in a model that mimicked the 
gastrointestinal tract disorders frequently present in anxiety, 
and this effect was reversed by BMY  14802 [52]. Subse-
quently, JO-1784 showed good results in clinical trials in a 
phase-1-model of functional diarrhea [213]. The results de-
scribed above (summarized in Table 4) suggest that 1 recep-
tors play an important role in the modulation of anxiety. 
4.3. Schizophrenia and 1 Receptors 
  The dopamine hypothesis of schizophrenia, which in-
volves enhanced mesolimbic dopamine function, remains the 
dominant hypothesis for the pathophysiology of this disor-
der, particularly regarding the appearance of positive symp-
toms [40]. In addition, it is important to consider the gluta-
matergic system. In fact, the blockade of NMDA receptors 
by PCP induces schizophrenia-like psychosis in humans [24, 
212]. Because several antipsychotics possess high to moder-
ate affinities for 1 receptors (Table 1), researchers were 
inspired to test 1 receptor ligands in several animal models 
of schizophrenia. 
4.3.1. Role of 1 Receptors in Behavioral Models of 
Schizophrenia in which Dopaminergic Function is Promi-
nently Enhanced 
  In behavioral animal models in which the dopaminergic 
function is affected, such as apomorphine-induced climbing, 
amphetamine-induced locomotor activity, and behavioral 
sensitization by the repeated administration of psychostimu-
lants, promising results have been reported using 1 antago-
nists (summarized in Table 5). The nonselective 1 antago-
nist BMY  14802, panamesine, E-5842 and MS-377 inhibit 
apomorphine-induced climbing [53, 187, 195, 201]. In addi-
tion, DTG, SR 31742A, panamesine, rimcazole and E-5842 
inhibit amphetamine-induced locomotor activity [53, 164, 
176, 187]. However, rimcazole and BD 1047 had little effect 
on apomorphine-induced climbing, and in addition, this latter 
compound had little effect on acute amphetamine-induced 
Table 3. Summary of the Involvement of 1 Receptors in Depression (see References and Text for Additional Information) 
Involvement of 1 Receptors in Depression 
 Effect  of  1 Agonists  Effect of 1 Antagonists 
Tail suspension test [207] 
Forced swimming test [121, 126, 185, 208, 
210, 218] 
Behavioral experimental models 
Olfactory bulbectomy [216] 
Improvement 
Reversion of the effects of 1
agonists 
Firing of serotonergic neurons [8, 203]  Potentiation 
Mechanisms associated with antidepres-
sant activity  Neurotrophic actions [198] 
Potentiation of growth factor-
induced neurite sprouting 
Reversion of the effects of 1
agonists 
Mechanisms associated with depression 
Decrease of NMDA receptor subunit 1 
[216] 
Reversion 
Reversion of the effects of 1
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hyperlocomotion [187]. In models of behavioral sensitization 
with the repeated administration of psychostimulants—a 
pharmacological model of schizophrenia [21]— 1 antago-
nism inhibited sensitization to methamphetamine [1, 196, 
205] and cocaine [206, 221]. It was therefore suggested that 
1 antagonists may be suitable for maintenance therapy in 
persons with stable schizophrenia rather than for the treat-
ment of acute psychotic features. 
4.3.2. Role of 1 Receptors in Behavioral Models of 
Schizophrenia in which Glutamatergic Function is Promi-
nently Disturbed 
  As said before, in addition to dopaminergic dysfunction, 
alterations in glutamatergic neurotransmission are also in-
volved in schizophrenia. Sigma1 ligands modified animal 
behavior in some glutamatergic models of this disease 
(summarized in Table 5). PCP-induced head weaving, which 
is insensitive to selective D2 antagonists, was attenuated by 
NE-100, haloperidol, BMY  14802, Dup 734 and MS-377 
[63, 195]. Recent reports also showed that BD 1047, rimca-
zole and panamesine attenuated PCP-induced head twitching 
[187]. In addition, selective 1 receptor agonists such as (+)-
pentazocine, and also 3-(+)-PPP and (+)-SKF-10,047, en-
hanced the psychotomimetic effect (hyperlocomotion) of 
dizocilpine in monoamine-depleted mice, and this enhance-
ment was blocked by NE-100 [157], suggesting that 1 re-
ceptor blockade may be effective for negative symptoms of 
schizophrenia, which are hypothesized to be mediated, at 
Table 5. Summary of the Involvement of 1 Receptors in Schizophrenia (see References and Text for Detailed Information) 
Involvement of 1 Receptors on Schizophrenia 
 Effect  of  1 Agonists  Effect of 1Antagonists 
Apomorphine-induced climbing [53, 
187, 195, 201] 
Amphetamine-induced locomotor activ-
ity [53, 164, 176, 187] 
Dopaminergic function 
prominently enhanced 
Behavioral sensitization induced by 
repeated administration of psychostimu-
lants [1, 196, 205, 206, 221] 
Not tested  Inhibition 
PCP-induced stereotyped behaviors [63,
187, 195] 
Not tested  Inhibition 
Dizocilpine-induced hyperlocomotion in
monoamine depleted mice [157] 
Enhancement 
Reversion of the effects 





PCP-induced cognitive deficits [58]  Improvement 
Reversion of the effects 
of 1 agonists 
Clinical trials  Only with BMY 14802, eliprodil and panamesine [61]  Not tested  Inconclusive results 
Table 4. Summary of the Involvement of 1 Receptors in Anxiety (see References Cited in the Text for Detailed Information) 
Involvement of 1 Receptors on Anxiety 
 Effect  of  1 Agonists  Effect of 1 Antagonists 
Conditioned fear stress [79, 80, 153, 211] 
Sexual dysfunction induced by stress [140] 
Marble-burying behavior test [44] 
Behavioral experimental models 
Colonic motor disturbances induced by fear 
[52] 
Improvement 
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least in part, by glutamatergic neurotransmission. Among the 
negative symptoms of schizophrenia, cognitive deficits are 
core features of the illness and predict vocational and social 
disabilities for patients [90]. It has been extensively reported 
that 1 agonists play an important role in memory processes 
(as described in the section 4.1., ‘Role of 1 receptors in 
learning and memory’). In fact, SA4503, DHEAS, and flu-
voxamine (a SSRI with high affinity for 1 receptors), but 
not paroxetine (an SSRI without affinity for 1 receptors) 
improved the PCP-induced cognitive deficits in the novel 
object recognition test, and these effects were antagonized by 
the co-administration of NE-100 [58]. In addition, the antip-
sychotic (and also 1 antagonist) drug haloperidol was inef-
fective in this behavioral model [57]. These results suggest 
that 1 agonists are potentially useful for the cognitive defi-
cits of schizophrenia. 
4.3.3. Sigma1 Receptors and Extrapyramidal Side Effects 
  The extrapyramidal effects of neuroleptics are considered 
one of the most problematic side effects of these drugs. It has 
been suggested that  receptors mediate the undesirable mo-
tor side effects of antipsychotic drugs [reviewed in 54 and 
214], an effect classically attributed to the 2 subtype [e.g., 
215]. Although it was found that the affinities of several neu-
roleptics for  receptors (both 1 and 2) correlated well with 
their risk of producing acute dystonic reactions [108], it is 
known that the blockade of 1 receptors with other more 
selective antagonists such as NE-100 [158], MS-377 [195], 
E-5842 [53] or BMY 14802 [50] (at effective doses for the 
test used) does not induce motor side effect. These findings 
suggest that the blockade of 1 receptors is not enough in 
itself to induce extrapyramidal side effects, so additional 
mechanisms are probably be involved. 
4.3.4. Clinical Trials with 1 Ligands in Schizophrenia 
  Some clinical trials have been done with rimcazole, 
BMY  14802, eliprodil (SL-82.0715) and panamesine. The 
trials with rimcazole and BMY 14802 yielded inconclusive 
results [reviewed in 61]; however, eliprodil reduced scores 
for negative but not positive symptoms, whereas panamesine 
reduced both positive and negative symptoms. However, a 
metabolite of panamesine has potent antidopaminergic prop-
erties which might explain its effect against the positive 
symptoms, so further research is needed to determine 
whether these effects are wholly or partly mediated by 1
receptors [reviewed in 61]. 
  In summary, due to the complex pathogenesis of schizo-
phrenia and the differential effects of 1 antagonists (which 
improve the behavior of animals in models based on the mo-
tor effects of dopaminergic stimulants or NMDA antago-
nists) and 1 agonists (which improve the cognitive deficits 
induced by PCP) (summarized in Table 5), treatment based 
exclusively on 1 ligands would probably be complex. 
4.4. Sigma1 Receptors and Analgesia 
 Sigma1 receptors are distributed in the central nervous 
system in areas of great importance in pain control, such as 
the superficial layers of the spinal cord dorsal horn, the 
periaqueductal gray matter, the locus ceruleus and rostroven-
tral medulla [2, 88]. As will be described below, they may be 
involved in the modulation of opioid analgesia, and may also 
play an important role in nociception in the absence of 
opioid drugs. 
4.4.1. Modulation of Opioid Analgesia by 1 Receptors 
  Chien and Pasternak were the first to report the involve-
ment of 1 receptors in analgesia [28]: they clearly demon-
strated that 1 receptors play an important role in the modu-
lation of opioid analgesia in the tail-flick test. The systemic 
administration of 1 agonists, including the selective 1 ago-
nist (+)-pentazocine, antagonized the antinociception in-
duced by morphine in the tail-flick test [28-30, 130]. Further 
experiments with other opioids confirmed the role of 1 re-
ceptors in opioid analgesia. (+)-Pentazocine also diminished 
-, 1-, and 3-opioid antinociception [29, 130, 173]. In addi-
tion, 1 antagonists such as haloperidol and (+)-MR 200 not 
only reversed the effects of agonists, but also increased 
opioid-induced antinociception, indicating the presence of a 
tonically active anti-opioid 1 system [28-30, 100, 173]. 
  The anatomical location of the modulation of opioid an-
algesia by 1 receptors has been determined with different 
routes of administration of opioids, 1 receptor ligands and 
antisense oligodeoxynucleotides. The intrathecal (i.t.) ad-
ministration of (+)-pentazocine did not reverse the spinal 
(i.t.) analgesic effect of morphine in the tail-flick test, sug-
gesting that the modulation of opioid analgesia by 1 recep-
tors in this test does not occur at the spinal level [130]. Inter-
estingly, the supraspinal (intracerebroventricular, i.c.v.) ad-
ministration of (+)-pentazocine decreased the analgesic ef-
fect of agonists for the  and F opioid receptors nalorphine 
and nalbuphine [130]; in addition, the analgesia induced by 
the supraspinal (i.c.v.) administration of the selective 
-opioid agonist DAMGO was enhanced by the 1 antago-
nist (+)-MR 200 administered subcutaneously [100]. Further 
experiments based on the selective blockade of 1 receptor 
synthesis by the i.c.v. administration of specific antisense 
oligodeoxynucleotides confirmed the supraspinal location of 
the modulation of opioid analgesia [87, 130, 161]. Finally, a 
more detailed approach was tested recently by Mei and 
Pasternak [131], who used microinjections of morphine in 
conjunction with (+)-pentazocine, haloperidol, or both in 
three brainstem nuclei: the periaqueductal gray, rostroventral 
medulla and locus ceruleus. The activity of 1 receptors was 
found to differ depending on the area. Whereas both the lo-
cus ceruleus and rostroventral medulla were sensitive to 
(+)-pentazocine, the periaqueductal gray was not. The ros-
troventral medulla was particularly interesting, because it 
was the only region with evidence for tonic 1 activity (en-
hanced by haloperidol), and it was also able to modulate the 
analgesia from morphine administered to the periaqueductal 
grey. 
  In contradistinction to results in the tail-flick test, it was 
found that the systemic administration of (+)-SKF-10,047 or 
NE-100 was unable to modulate 1 opioid analgesia in the 
acetic acid-induced writhing test [66]. Although the doses 
used in this study might have been too low to prevent the 
participation of 1 receptors in the modulation of 1 opioid 
analgesia in the acetic acid-induced writhing, i.c.v. treatment 
with 1 antisense oligodeoxynucleotides also failed to affect 
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of 1 receptors does not affect  opioid analgesia in this be-
havioral test. This findings may indicate that the supraspinal 
 system modulates only some opioid analgesic effects, 
probably depending on the type of pain evaluated (i.e., de-
pending on the behavioral model used). Further research 
with different models is needed to characterize the role of the 
supraspinal  system in opioid analgesia. The role of 1 re-
ceptors on opioid analgesia in behavioral experimental mod-
els is summarized in Table 6.
  In addition, some recent reports showed that haloperidol 
and chlorpromazine, two neuroleptics that bind to  sites 
(Table 1), inhibit the antianalgesia induced by nalbuphine in 
men [48]. Although the authors did not attribute this inhibi-
tion to  receptors, this possibility cannot be fully ruled out, 
and would suggest that interaction between the  and opioid 
systems is important in clinical terms. However, this issue 
also needs to be addressed in further clinical studies. 
4.4.2. Analgesic Effect of 1 Receptor Ligands 
  The role of 1 ligands in the absence of opioid drug has 
also been investigated. Several 1 ligands or antisense treat-
ments have been proved to be inactive in the tail-flick test 
[22, 28-30, 100, 130, 161], as well as in the acetic acid-
induced writhing test [66, 67] (although higher doses of 1
ligands should be tested to ensure their lack of involvement 
in acetic acid-induced writhing). However, other reports 
showed that 1 receptors are able to modulate nociception in 
other behavioral tests in the absence of an opioid drug. Ueda 
andcoworkers[204] showed that the 1 agonists (+)-pentazo-
cine and SA4503, (+)-3-PPP, and also the putative 1 ago-
nists DHEAS and pregnenolone sulfate (administered intra-
plantarly) can induce nociception even when used alone in 
the nociceptive flexor response test. The effect of the 1 ago-
nists was reverted by the known 1 antagonists NE-100, 
BD 1047 or the putative 1 endogenous antagonist proges-
terone [204]. Other studies in our laboratory with the forma-
lin test showed that formalin-induced nociception was at-
tenuated not only by the systemic administration of haloperi-
dol, haloperidol metabolite II and haloperidol metabolite I 
(with an order of potency which correlated with their affinity 
for 1 receptors) [22], but also in 1 receptor knockout mice 
[23]. Recent experiments with the same behavioral test found 
that in contradistinction to the supraspinal action of 1 an-
tagonists on the modulation of opioid analgesia, the i.t. ad-
ministration of the 1 receptor antagonists BD  1047 and 
BMY  14802 dose-dependently reduced formalin-induced 
pain behaviors in the second phase but not in the first phase 
of the formalin test [86]. This underscored the importance of 
spinal 1 receptors in the second phase of formalin-induced 
pain. These results were consistent with previous findings 
which showed that haloperidol, haloperidol metabolite I and 
haloperidol metabolite II were more effective in the second 
than in the first phase of formalin-induced pain [22]. In 
agreement with these behavioral studies, it was also reported 
that antagonism of spinal 1 receptors suppressed phosphory-
lation of the NR1 subunit of spinal NMDA receptors [86], 
which are important for maintaining spinal sensitization as-
sociated with the second phase of the formalin test [190]. 
From these results it was proposed that 1 receptors may be 
important in models in which spinal sensitization occurs 
(without ruling out other analgesic effects in other models), 
and in fact, the putative 1 agonist DHEA induced mechani-
cal allodynia and thermal hyperalgesia when administered 
i.t., and the effects were reversed by BD  1047 [85]. This 
hypothesis deserves further investigation in other models of 
pain, especially in models of tonic pain in which central sen-
sitization occurs. The results obtained in the behavioral mod-
Table 6. Summary of the Involvement of 1 Receptors in Analgesia (see Text and References for Detailed Information, as Admini-
stration Routes of Drugs) 
Involvement of 1 Receptors on Analgesia 
  Behavioral Experimental Models  Effect of 1Agonists Effect  of  1Antagonism 
Tail-flick test [28-30, 87, 100, 130, 
161, 173] 
Inhibition Enhancement 
Modulation of opioid 
analgesia 
Acetic acid-induced writhings [66, 67]
Inactive 
(very low doses tested)
a
Inactive 
(very low doses tested)
a
Tail-flick test [22, 28-30, 100, 130, 
161] 
Inactive Inactive 
Acetic acid-induced writhings [66, 67]
Inactive 
(very low doses tested)
a
Inactive 
(very low doses tested)
a
Nociceptive flexor response test [204] Nociception  Reversion of the effects of 1 agonists 
Formalin-induced pain [22, 23, 86]  Reversion of the effects of 1 antagonists  Antinociception 
Plantar test [85]  Thermal hyperalgesia
b  Reversion of the effects of 1 agonists 
Pain modulation in the 
absence of opioid drugs 
von Frey test [85]  Mechanical allodynia
b  Reversion of the effects of 1 agonists 
a Additional experiments using higher doses of 1 ligands should be performed.
bSelective1 agonists should be tested. 358    Current Neuropharmacology, 2008, Vol. 6, No. 4 Cobos et al. 
els described above (summarized in Table 6) suggest that 1
receptors play an important role in nociception in the ab-
sence of opioid drugs. 
 In  summary,  1 receptors are not only able to modulate 
opioid antinociception, at least in the tail-flick test, but may 
also play an active role in nociception in the absence of 
opioid drugs in some behavioral models (see Table 6).  
4.5. Sigma1 Receptors and Drugs of Abuse 
  As shown before (Table 1), 1 receptors can bind several 
drugs of abuse. It is therefore not surprising that 1 ligands 
can modulate some of the effects of these drugs. Among the 
drugs of abuse studied to date, the involvement of 1 recep-
tors in the actions of cocaine has been extensively investi-
gated, but 1 receptors also appear to underlie the effects of 
other substances such as methamphetamine, MDMA (3,4-
methylenedioxymethamphetamine) and ethanol, as will be 
described below. 
4.5.1. Cocaine and 1 Receptors 
  Cocaine is generally thought to act as a dopamine re-
uptake inhibitor to produce its reinforcing effects, although 
other mechanisms might also be important [105]. Cocaine 
binds preferentially to 1 receptors rather than to 2 [111], 
and the affinity of cocaine for 1 receptors is in the micromo-
lar range (Table 1), as is its affinity for its main pharmacol-
ogical target, the dopamine transporter (DAT) [175]. Co-
caine levels in the post-mortem brain of addicts were esti-
mated to be between 0.1 and 4 M [78], which is close to the 
Ki value of cocaine for 1 receptors. In recent years several 
excellent and promising studies have been performed with 1
ligands against the effects of cocaine, as described below. 
4.5.1.1. Modulation by 1 Receptors of the Acute Effects of 
Cocaine 
  The ability of compounds to attenuate the acute locomo-
tor effects of cocaine is often used as an initial screening tool 
to identify agents able to block the psychostimulant activity 
of this drug of abuse. Convulsions and lethality, on the other 
hand, represent a measure of cocaine toxicity, and can result 
from exposure to acute large doses. Many 1 antagonists 
have been reported to significantly prevent the acute locomo-
tor stimulatory effects, convulsions or lethality induced by 
cocaine in rodents, including haloperidol, BD 1008 (and 
some of its analogs such as the selective 1 antagonists 
BD 1047 and BD 1063), BMY 14802, panamesine and rim-
cazole (and some of its analogs), among others [partially 
reviewed in 112 and 124; 37, 95, 113]. Furthermore, the ad-
ministration of antisense oligodeoxynucleotides that knock 
down brain 1 receptors mimicked the effects of pharmacol-
ogical 1 antagonism on the locomotor stimulatory effects or 
convulsions induced by cocaine [109, 111]. Particularly in-
teresting are the studies in which post-treatment of mice with 
the novel  receptor antagonists LR132 and YZ-011, after 
cocaine administration, also attenuated cocaine-induced le-
thality after an overdose. However, BD 1063 was unable to 
prevent death under these conditions, and the authors hy-
pothesized that this result was due to differences in pharma-
cokinetics [109, 111]. The ability of  receptor antagonists to 
prevent death after an overdose of cocaine in animals sug-
gests a clinical application potentially worth further study. In 
contradistinction to the positive effects of 1 antagonists, the 
administration of DTG, the novel 1 agonists BD1031 and 
BD1052, or the selective 1 agonist SA4503 exacerbated 
locomotor stimulatory actions and the toxic effects (meas-
ured as convulsions and lethality rate) of the acute admini-
stration of cocaine [109, 111, 129, 184]. The results obtained 
in these behavioral models (summarized in Table 7) suggest 
that 1 receptors play an important role in the acute effects of 
cocaine. In addition to 1 receptors, it has been proposed that 
the 2 subtype might also be a good pharmacological target 
against cocaine-induced actions [partially reviewed by 113; 
114, 156]. 
4.5.1.2. Modulation by 1 Receptors of the Effects of Re-
peated Cocaine Administration
 Several  1 antagonists have also been tested in behavioral 
models that used repeated doses of this drug of abuse. The 1
antagonists rimcazole and some of its analogs, and other 
putative  antagonists did not alter or only slightly altered 
the discriminative stimulus of cocaine [83, 95, 221], indicat-
ing that the interaction between cocaine and  receptor 
ligands might be more complex than an exclusively competi-
tive antagonism. Other studies that involved the repeated 
administration of cocaine found that  receptor antagonists 
significantly prevented the development of cocaine-induced 
locomotor sensitization [206, 221], which is considered a 
measurable index of nervous system plasticity resulting from 
repeated exposure to cocaine [112]. The effects of 1 antago-
nism on the rewarding properties of this drug of abuse have 
been explored with promising results. In the conditioned 
place preference test, the selective 1 receptor antagonists 
BD 1047 and NE-100 attenuated the acquisition [168, 169] 
and also the expression of cocaine-induced conditioned place 
preference [169]. In addition, treatment with 1 antisense 
oligodeoxynucleotide was effective against the acquisition of 
conditioned place preference, indicating the specificity of 
these effects [168]. However, in cocaine self-administration 
experiments, Martin-Fardon and coworkers found that 
BD 1047 was inactive against the acute reinforcing effects of 
cocaine, supposedly because both the reinforcing quality and 
relevant neuroadaptive changes are likely to differ in rats 
subjected to involuntary administration (as in conditioned 
place preference) vs. self-administration of cocaine [101]. 
After extinction, cocaine addictive behavior can be reacti-
vated by a discriminative stimulus associated with cocaine 
administration, or by a priming injection of cocaine (in self-
administration or conditioned place preference experiments, 
respectively). These processes were both blocked by BD 
1047 [101, 170], and the latter one was also blocked by 1
antisense oligodeoxynucleotides [170]. Interestingly, the 1
agonists PRE 084 and JO-1784 were unable to induce condi-
tioned place preference [169], but the administration of the 
latter 1 agonist, or even DHEA, was enough to reactivate 
conditioned place preference after extinction, in a BD 1047-
sensitive manner [170]. The results in these behavioral mod-
els (summarized in Table 7) suggest that 1 receptors play an 
important role in neuronal plasticity after repeated cocaine 
administration, and that 1 antagonists could be useful to 
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  It has been reported that 1 receptor density changes after 
repeated treatment with cocaine [96, 169, 170, 183, 223]. 
Particularly interesting is the 1 receptor upregulation in the 
caudate putamen (an important area in the drug reward 
mechanism), which was not produced in dopamine D1 recep-
tor knockout mice [223]. Consistent with this finding was 
that cocaine treatment in the neuroblastoma cell line B-104 
(lacking in dopamine transporter or receptors), was also un-
able to induce 1 receptor upregulation [36], suggesting a 
close relationship between dopamine and 1 receptors. In 
fact, it has been proposed that both D1 receptors and 1 re-
ceptors are involved in cocaine-induced life-long alterations 
in neurons [194]. 
4.5.1.3. Effects of 1 Ligands on Cocaine-Induced Immune 
System Depression
  Different experiments have been designed to investigate 
the effects of cocaine other than its acute toxicity or reward-
ing properties, specifically, modulation of the immune sys-
tem by cocaine. It was recently reported that cocaine can 
enhance alveolar cell carcinoma growth in mice, and that this 
effect was mimicked by PRE 084 and reversed by BD 1047. 
Increased tumor growth induced by cocaine or PRE 084 was 
accompanied by an increase in IL-10 and a decrease in IFN-
production [46]. In addition, the selective 1 antagonist 
BD 1047 blocked enhancement of the replication of HIV-1 
in mice with severe combined immunodeficiency implanted 
with HIV-1-infected human peripheral blood mononuclear 
cells [174], and also in human microglial cell cultures [49]. 
These reports suggest that 1 receptors are involved in the 
cocaine-induced depression of the immune system. 
 In  summary,  1 antagonists appear to be potentially use-
ful not only against acute cocaine toxicity or addiction, but 
also against the noxious modulation of the immune system in 
cocaine consumers. In addition, 1 agonists, as described in 
section 4.1. ‘Role of 1 receptors in learning and memory,’ 
may be useful against some behavioral alterations induced 
by repeated cocaine exposure in utero. It therefore seems 
clear that cocaine produces its behavioral and biochemical 
effects, at least in part, through its interaction with 1 recep-
tors, and that 1 ligands should be considered for the devel-
opment of potential therapies to treat different aspects of 
cocaine abuse. 
4.5.2. Other Drugs of Abuse and 1 Receptors 
  Methamphetamine, like cocaine, also binds to 1 recep-
tors in the micromolar range (Table 1), and with a 20-fold 
higher affinity than for 2 receptors [151], so it is not unex-
pected that 1 ligands modulate some effects of this psy-
chostimulant. Early studies found that the 1 antagonists NE 
100, BMY 10802 and MS-377 modulated the acute motor 
Table 7. Summary of the Involvement of 1 Receptors in the Behavioral Effects Induced by Cocaine (see References and Text for 
Detailed Information) 
Involvement of 1 Receptors in Cocaine-Induced Behavioral Effects 
Behavioral Experimental
Model 




Locomotor activity [37, 95,
111, 109, 112, 124] 
Convulsions [37, 109, 111,
112, 113, 124] 
Acute effects of cocaine 
Toxicity 
Lethality [37, 112, 113, 
124] 
Potentiation Inhibition 
Self-reported effects of cocaine 
Drug discrimination test 
[83, 95, 221] 
Not tested  Slight or no effect 
Nervous system plasticity 
Locomotor sensitization 
[206, 221] 
Not tested  Inhibition 
Conditioned place prefer-
ence [168, 169] 
Not tested  Inhibition 
During addictive 
behavior 
Self-administration [101]  Not tested  No effect 
Conditioned place prefer-
ence after priming injection





After extinction of 
addictive behavior  Discriminative stimulus 
associated with cocaine 
availability for self-
administration [101] 
Not tested  Inhibition 360    Current Neuropharmacology, 2008, Vol. 6, No. 4 Cobos et al. 
effects of methamphetamine only weakly, if at all [158, 196, 
205]. However, more recent studies showed that the selective 
1 antagonists BD 1063 and BD 1047, as well as 1 antisense 
oligodeoxynucleotide, inhibited methamphetamine-induced 
locomotor activity [151]. It was also recently reported that 
like cocaine or methamphetamine, the compound MDMA 
(‘ecstasy’), which is structurally related to methampheta-
mine, showed preferential affinity for 1 receptors rather 
than for the 2 subtype, and that BD 1063 also attenuated the 
locomotor activity induced by this compound [15]. Further-
more, BMY 14802 and MS-377, two known 1 antagonists, 
inhibited the behavioral sensitization induced by the repeated 
administration of methamphetamine [1, 196, 205]. As in 
studies with repeated cocaine administration, it was thought 
that 1 receptors might play a role in neuronal plasticity after 
the repeated administration of methamphetamine. Sigma1
receptor levels were recently found to be unaltered in rats 
passively treated with this psychostimulant; however, in rats 
self-administered with methamphetamine, 1 receptors were 
upregulated in the rat midbrain, an area involved in learning 
and reward processes, but not in the cerebellum, frontal cor-
tex, striatum and hippocampus. These observations under-
scored the role of 1 receptors in neuronal plasticity after the 
consumption of psychostimulants [191]. 
  The role of 1 receptors in the behavior of other drugs of 
abuse has also been explored, and it was found that the 1
antagonist BD  1047 was effective against ethanol-induced 
locomotor stimulation, conditioned place preference, taste 
aversion and some symptoms of the abstinence syndrome 
after chronic ethanol consumption [125, 135]. Interestingly, 
1 receptor expression was increased in the hippocampus of 
mice after chronic ethanol consumption. However, both the 
1 agonist JO-1784 and the antagonist BD 1047 shared some 
ameliorating properties against the abstinence syndrome af-
ter chronic ethanol consumption [135]. These observations 
suggest a new pharmacological target for alleviating ethanol 
addiction and abstinence syndrome after withdrawal, al-
though more behavioral tests should be performed. Interest-
ingly, an association has been suggested between polymor-
phisms in the 1 receptor gene and alcoholism [139], sup-
porting the role of 1 receptors in chronic ethanol consump-
tion. 
5. CONCLUSIONS AND PERSPECTIVES 
  At the present time it seems logical to attribute the neu-
ropharmacological properties of 1 ligands to the neuro-
modulatory role of 1 receptors. They act as intracellular 
amplifiers for signal transductions involving InsP3 receptors, 
areclearlyable to modulate neurotransmitter systems (mainly 
through NMDA receptors) and ion channels (such as K
+
channels), and may play an important role in neuroplasticity 
processes. Because of this typically modulatory nature of 1
receptors, 1 ligands are usually devoid of effect per se under 
control conditions in many experimental situations. In fact, 
and in agreement with the modulatory role of 1 receptors, 1
knockout mice do not display any overt phenotype. How-
ever, data showed that 1 ligands are highly active when a 
pharmacological or pathological imbalanced state arises. In 
addition, and also due to the modulatory role of 1 receptors, 
the combined administration of 1 receptor ligands and 
medications with a known therapeutic effect has been shown 
to improve the effects of the latter (at least in behavioral 
models of depression and in opioid-mediated analgesia), 
resulting in the need for lower doses to reach therapeutic 
concentrations. This synergistic action of 1 ligands and low 
doses of other known drugs merits further study in additional 
behavioral models. Of particular interest is the bell-shaped 
dose-response curve of 1 agonists in in vitro experiments, in 
behavioral tests in which 1 agonists are active (i.e., learning 
and memory processes, depression and anxiety), and even in 
some clinical trials. These data strongly suggest that re-
searchers should take hormesis into account in order to de-
sign informative experiments or clinical trials with 1 ago-
nists. 
  In the light of our current knowledge, it seems clear that 
1 agonists are promising pharmacological tools against 
memory and learning disorders, and also against depression 
and anxiety. Although some previous findings suggest that 
1 antagonists might be potentially useful tools against some 
symptoms of schizophrenia, currently the most promising 
therapeutic targets for 1 antagonism are nociception and 
some deleterious effects of certain drugs of abuse (such as 
cocaine, methamphetamine and ethanol). Importantly, many 
drugs used routinely in therapeutics show affinity for 1 re-
ceptors (see Table 1), and exert the same effects as other 
more selective 1 ligands in many behavioral tests and in
vitro assays. Therefore, the therapeutical properties of these 
drugs might be due, at least in part, to their interaction with 
1 receptors. Interestingly, several drugs have been proved to 
be effective against diseases (in behavioral animal models) 
different from those for which they are prescribed in clinical 
practice, through their interaction with 1 receptors. These 
findings raise the possibility of new therapeutic applications 
with drugs routinely used in therapeutics.
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